妇科恶性肿瘤临床试验中导致美国食品药品监督管理局批准的种族和民族入组差异
该横断面研究分析了2010至2024年间获美国食品药品监督管理局批准的妇科恶性肿瘤临床试验的种族/民族入组比例,以美国2016至2020年妇科癌症患病率为基准计算入组分数。结果显示非西班牙裔黑人和西班牙裔患者显著入组不足,而非西班牙裔白人及亚裔患者入组比例相对较高。
要点
- 非西班牙裔黑人患者入组不足(OR 0.50,95%CI 0.45-0.54,P<.001)。
- 西班牙裔患者入组不足(OR 0.69,95%CI 0.61-0.78,P<.001)。
- 亚裔患者入组比例过高(OR 2.81,95%CI 2.64-2.99,P<.001)。
核心结论
- 在主要于北美和欧洲开展的、导致美国食品药品监督管理局批准妇科恶性肿瘤的临床试验中,以美国妇科癌症女性人群为基准,非西班牙裔黑人和西班牙裔患者较非西班牙裔白人参与者显著入组不足,这些试验未能充分反映美国诊断为这些恶性肿瘤的人群。
研究设计与样本
- 横断面研究,分析2010至2024年间在ClinicalTrials.gov注册并获得美国食品药品监督管理局妇科恶性肿瘤新批准的临床试验,排除未在北美或欧洲开展的研究。
- 共31项研究符合纳入标准,其中21项报告了种族/民族数据;参与者中位数为494例(四分位距150-674)。
- 15项为III期试验,6项为IB/II期试验;治疗包括免疫检查点抑制剂(7项)、聚(ADP-核糖)聚合酶抑制剂(5项)、血管内皮生长因子抑制剂(4项)、抗体-药物偶联物(4项)和影像标志物(1项)。
- 所有研究共纳入11,258例患者,其中卵巢癌研究5,563例(49.4%)、子宫内膜癌研究2,963例(26.3%)、宫颈癌研究2,732例(24.3%)。
主要发现
- 3项研究(n=1,734)将参与者二分为非西班牙裔白人和非白人;非西班牙裔白人1,291例(74.4%),非白人443例(25.6%);入组分数非西班牙裔白人为0.51%,非白人为0.43%,非白人入组不足(OR 0.85,95%CI 0.76-0.95,P=.004)。
- 在报告种族类别的18项研究分析中,非西班牙裔黑人患者显著入组不足(OR 0.50,95%CI 0.45-0.54,P<.001),而亚裔患者入组比例过高(OR 2.81,95%CI 2.64-2.99,P<.001)。
- 在报告民族属性的4项研究中,西班牙裔患者也显著入组不足(OR 0.69,95%CI 0.61-0.78,P<.001)。
临床怎么用
- 作者认为,亟需采取入组策略以增加多样性,确保临床试验结果公平且适用于所有人群。
- 作者指出,美国临床肿瘤学会、社区癌症中心协会和妇科肿瘤学组/妇科肿瘤学会包容、多样性、公平与可及性倡议为达成此目标提供了全面框架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Compared to White women, Black women and other minority groups have a higher age-adjusted incidence risk of cervical and endometrial cancer. However, the extent of racial and ethnic disparities in clinical trial enrollment among studies performed mainly in North America and Europe for gynecologic malignancy is unknown. OBJECTIVE: This study analyzed enrollment rates by race/ethnicity in trials that led to Food and Drug Administration approvals for gynecological cancers from 2010 to 2024. STUDY DESIGN: This cross-sectional study examined clinical trials registered with ClinicalTrials.gov that resulted in new Food and Drug Administration approvals for gynecologic malignancies between 2010 and 2024. Exclusion criteria were studies not conducted in North America or Europe. Enrollment fractions were obtained by dividing the number of trial participants segregated by the racial/ethnic group by the corresponding U.S. cancer prevalence (uterine, ovarian, and cervical cancer) for 2016 to 2020 for each racial/ethnic group. Odds ratios and 95% confidence intervals were calculated to compare enrollment fractions of minority groups to non-Hispanic Whites. RESULTS: A total of 31 studies met the inclusion criteria, with 21 reporting race/ethnicity data. Three (3/21) studies dichotomized race as non-Hispanic White and non-White and 7 (7/21) reported ethnicity. The median number of participants was 494 [interquartile range 150-674]. Fifteen studies were phase III, and 6 were phase IB/II trials. Treatments included immune checkpoint inhibitors (7 studies), poly (ADP-ribose) polymerase inhibitors (5), vascular endothelial growth factor inhibitors (4), antibody-drug conjugates (4), and an imaging marker (1). Across all studies, 11,258 patients were included, 5563 (49.4%) in ovarian cancer studies, 2963 (26.3%) in endometrial cancer studies, and 2732 (24.3%) in cervical cancer studies. Three studies (n=1734) dichotomized participants into non-Hispanic White and non-White; non-Hispanic White 1291 [74.4%] and non-White 443 [25.6%], and enrollment fractions were 0.51% for non-Hispanic White and 0.43% for no-White, with non-White being underrepresented odds ratio 0.85, 95% confidence interval [0.76-0.95], P=.004. In an Analysis of 18 studies reporting race categories, non-Hispanic Black patients were significantly underrepresented (odds ratio 0.50, 95% confidence interval [0.45-0.54], P<.001), while Asian patients were overrepresented (odds ratio 2.81, 95% confidence interval [2.64-2.99], P<.001). In the 4 studies reporting ethnicity, Hispanic patients were also significantly underrepresented (odds ratio 0.69, 95% confidence interval [0.61-0.78], P<.001). CONCLUSION: In clinical trials, performed in North America and Europe mainly, leading to Food and Drug Administration approvals for gynecologic malignancies, non-Hispanic Black and Hispanic patients are significantly underrepresented compared to non-Hispanic White participants when enrollment is benchmarked to the U.S. female population with gynecological cancer. These trials do not adequately reflect the U.S. populations diagnosed with these malignancies. Enrollment strategies to increase diversity are urgently needed to ensure clinical trial results are equitable and applicable across all populations. Efforts from the American Society of Clinical Oncology, the Association of Community Cancer Centers, and the Gynecologic Oncologic Group/Society of Gynecologic Oncology Inclusion, Diversity, Equity, and Access initiative provide a comprehensive framework for achieving this goal.
引用
- Levin G, Monk BJ, Pothuri B, et al. Racial and ethnic enrollment disparities in clinical trials leading to Food and Drug Administration approvals for gynecologic malignancies. Am J Obstet Gynecol. 2025. PMID: 39863035. doi:10.1016/j.ajog.2025.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。